New mutations in TP53 gene drive resistance to p53-targeted cancer therapy

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
Technology Networks

Single-Cell Method Maps Pre-Malignant Mutations in Solid Tissues

Researchers developed a single-cell sequencing method that simultaneously measures cancer-linked DNA mutations and gene ...
GEN

Mapping Cancer Drug Resistance Mutations and Mechanisms

A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
Science Daily

AI unlocks genetic clues to personalize cancer treatment

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...
Labroots

Cell Mutation Predicts Chemotherapy Response in Bladder Cancer

The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.
News Medical

Co-occurring mutations may limit effectiveness of KRAS G12C inhibitors in colorectal and pancreatic cancer

Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...
The University of Chicago Chronicle

UChicago scientists decode key mutation in many cancers

Inside every cell, inside every nucleus, your continued existence depends on an incredibly complicated dance. Proteins are constantly wrapping and unwrapping DNA, and even minor missteps can lead to ...

New Data Underscoring Ability of Leapfrog Bio's OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal

Study highlights importance of cancer driver biology in translating results from lab to patients -- -- Findings validate proprietary OncoSLX Platform (TM), a pharmacogenetic approach that captures the ...